Skip to main content

Diagnostic and Therapeutic Use of Membrane Proteins in Cancer Cells

Buy Article:

$68.00 + tax (Refund Policy)

As proteomics technologies develop, increasing number of membrane-associated proteins specific for cancer cells are being discovered. These proteins are of great interest, particularly because they are rich in targets for antibodies. Amongst them candidate biomarkers for early tumor diagnosis, prognosis and treatment have been detected.

The suitability of several membrane-associated proteins as targets for drugs or antibodies has already been tested in preclinical and clinical studies. The results were encouraging in some cases, but not in all. They demonstrate that each type of tumor has its specific “Achilles heel”, and that suitable targets of cancer diagnosis and therapy must be found for each kind of neoplasm.

This implies that membrane-associated proteins for each type of tumor cell need to be investigated. This review describes the current technologies of membrane protein characterization in a first part and subsequently summarizes the membrane associated proteins currently being tested as targets for diagnosis and treatment in breast, prostate, thyroid, and colon cancer. Their function will be explained and their role in tumor biology will be discussed.

Keywords: 2D electrophoresis; Achilles heel; Bevacizumab; C cells; Cetuximab; Ertumaxomab; Helicobacter pylori; Ibuprofen; Immunological methods; Lapatinib; Liquid chromatography; N-acetyl-glucosamine; Neratinib; Paclitaxel; Panitumumab; Proteomics; R-Flurbiprofen; Sunitinib; Trastuzuma; biomarker; biotinylation; breast cancer; carbohydrate moieties; carcinoembryonic antigen; colorectal cancer; cytosolic proteins; eukaryotic cells; glycoprotein A33; glycosylphosphatidylinositol; heat shock pro-tein 90; hormone-refractory prostate cancer (HRPC); hyaluronan; immunoglobulin; iodine transporters; isoelectric focusing; laser microdissection; lipid bilayer; malignant cell; malignant cells; mass spectrometry; metastasis; neoplasm; papilloma virus; para-follicular; prostate cancer; proteomics technologies; radiotherapy; somatostatin receptor; threonine residues; thyroid cancer; thyroid gland; thyroid stimulating hormone (TSH); thyrotrophin; tumor neovascularization; tumorigenesis; tyrosine kinases

Document Type: Research Article

Publication date: 01 January 2011

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content